5－氟尿嘧啶－卟啉化合物的合成及抗癌活性

以37％－45％的产率合成了六个新的5－氟尿嘧啶-卟啉化合物，通过元素分析 、红外光谱、紫外可见光谱、核磁共振谱和质谱确定了其结构。抗癌试验表明，化 合物A3，A4，A5对Hela（宫颈癌细胞）有明显的抑制作用。     

Simultaneous determination of capecitabine and its metabolite 5-fluorouracil by column switching and liquid chromatographic/tandem mass spectrometry

A liquid chromatographic/tandem mass spectrometric method was developed and validated for the quantitation of capecitabine and its metabolite 5-fluorouracil in human plasma. The simultaneous determination of both analytes was achieved by a column switching method using a trapping column and two analytical columns with different stationary phases. Isocratic elution was used for the separation of capecitabine on a C18 column whereas 5-fluorouracil was separated using gradient elution on an non-polar carbon phase. The calibration curves were linear for both compounds with a correlation factor (R2) > 0.9993 for 5-fluorouracil and >0.9942 for capecitabine. The assay was validated in the concentration range 5.00-1000 ng ml(-1) for both compounds. The intra-day precision was better than 10% for 5-fluorouracil and better than 11% for capecitabine whereas the inter-day precision was better than 8% for 5-fluorouracil and better than 14% for capecitabine.     

新型N1-(2-呋喃烷基)-5-氟脲嘧啶的α-羟基(硫代)膦酸酯衍生物的合成

通过对N^1-(2－呋喃烷基）－5－氟脲嘧啶的氧化以及与O,O－二乙基硫代亚磷酸酯的加成反应合成了新型N^1-(2－呋喃烷基）－5－氟脲嘧啶的α-羟基（硫代）膦酸酯衍生物,进一步以间氯过氧苯甲酸氧化得到相应的α-羟基膦酸酯衍生物 。     

5-氟尿嘧啶壳聚糖微球的制备及其释药性能

5-氟尿嘧啶壳聚糖微球的制备及其释药性能;药物缓释剂     

Synthesis and Anticancer Properties of Rare Earth Substituted Tungstophosphoric Polyoxometalate Containing 5-Fluorouracil

Three novel rare earth substituted polyoxometalates containing 5‐fluorouracil, K₁₀C₄H₄FN₂O₂Pr(PW₁₁O₃₉)₂·24H₂O, K₁₀C₄H₄FN₂O₂Nd(PW₁₁O₃₉)₂·12H₂O and K₁₀C₄H₄FN₂O₂Sm(PW₁₁O₃₉)₂·12.5H₂O were synthesized and structurally characterized by elemental analysis, IR spectra, X‐ray powder diffraction and ¹⁸³W NMR. The results indicate that the compounds have Keggin structure of heteropolyanion and ring structure of 5‐fluorouracil. The cytotoxicity test of the compounds in human renal embryonic cell HEK293 and the activity inhibiting human cervical carcinoma cell Hela were studied by the methyl thiazolyl tetrazolium method with 5‐fluorouracil for the positive control group. The toxicity of the compounds are lower than that of 5‐fluorouracil. K₁₀C₄H₄FN₂O₂Pr(PW₁₁O₃₉)₂·24H₂O has no apparent toxicity in vitro and can inhibit Hela cells in vitro with significant difference compared with 5‐Fu.     

N(1)取代5-氟尿嘧啶乙酸、5-氟尿嘧啶丙酸与Cu(Ⅱ)、Co(Ⅱ)、Ni(Ⅱ)、Zn(Ⅱ)、Mn(Ⅱ)的配合物的合成及表征

合成了N(1)取代5-氟尿嘧啶乙酸、5-氟尿嘧啶丙酸与铜(Ⅱ)、钴(Ⅱ)、镍(Ⅱ)和锰(Ⅱ)的十种金属配合物。通过元素分析、差热-热重分析确定了它们的化学组成,并对这些化合物进行了红外光谱、氢核磁共振谱,电子光谱的表征。讨论了各配合物中金属离子与配体的配位状态。在Cu(Ⅱ)配合物中,Cu(Ⅱ)是与配体的N³原子和C⁴上的羰基氧原子配位,其他金属配合物中,金属离子是与配体的C²的羰基氧原子和羧基配位。     

Syntheses and antitumor activities of polymers containing amino acid and 5‐fluorouracil moieties

The new monomer, 3,6‐endo‐methylene‐1,2,3,6‐tetrahydrophthalimidoethanoyl‐5‐fluorouracil (ETEFU), was synthesized from 5‐fluorouracil (5‐FU) and 3,6‐endo‐methylene‐1,2,3,6‐tetrahydophthalimidoethanoyl chloride (ETEC). Its homopolymer and copolymers with acrylic acid (AA) and vinyl acetate (VAc) were prepared by photopolymerization reactions using 2,2‐dimethoxy‐2‐phenylacetophenone (DMP) as the photoinitiator. The synthesized ETEFU and polymers were identified by FT‐IR, ¹H‐NMR, and ¹³C‐NMR spectra. The contents of ETEFU units in poly(ETEFU‐co‐AA) and poly(ETEFU‐co‐VAc) were 20 and 17 mol%, respectively. The number‐average molecular weights of the synthesized polymers determined by gel permeation chromatography (GPC) were 4,600 to 10,700 g mol⁻¹. In vitro cytotoxicities of samples were evaluated with cancer cell lines [mouse mammary carcinoma (FM3A), mouse leukemia (P388), and human histiocytic lymphoma (U937)] and a normal cell line [mouse liver cells (AC2F)]. Cytotoxicities of 5‐FU and synthesized samples against the cancer cell lines were ranked as follows: ETEFU > poly(ETEFU) > 5‐FU > poly(ETEFU‐co‐AA) > poly(ETEFU‐co‐VAc). The in vivo antitumor activities of poly(ETEFU) and poly(ETEFU‐co‐AA) against Balb/C mice bearing the sarcoma 180 tumor cells were greater than those of 5‐FU at all doses except for the activity of poly(ETEFU) at 0.8 mg/kg. © 1999 John Wiley & Sons, Inc. J Polym Sci A: Polym Chem 37: 1589–1595, 1999     

Preparation of 5‐Fluorouracil‐Poly(L‐lactide) Microparticles Using Solution‐Enhanced Dispersion by Supercritical CO2

Summary: 5‐Fluorouracil‐poly(L ‐lactide) (5‐Fu‐PLLA) microparticles have been prepared by an SEDS process. First, the 5‐Fu is successfully micronized and is then used to produce the 5‐Fu‐PLLA microparticles. The 5‐Fu‐PLLA microparticles synthesized by the SEDS process exhibit a rather spherical shape and a narrow particle size distribution, where it ranges from 615 to 1 990 nm, with a mean particle size of 980 nm. The dichloromethane residue in the 5‐Fu‐PLLA microparticles without any further treatment is 46 ppm. The average drug load and encapsulation efficiency of the 5‐Fu‐PLLA microparticles are 3.05 and 17.8%, respectively. The rate of drug release from the 5‐Fu‐PLLA microparticles shows mainly first‐order kinetics.

Scanning electron spectroscopy image of 5‐Fu‐PLLA microparticles.     

Use of 5‐Fluorouracil Loaded Micelles and Cisplatin in Thermosensitive Chitosan Hydrogel as an Efficient Therapy against Colorectal Peritoneal Carcinomatosis

Colorectal peritoneal carcinomatosis (CRPC) is a common systemic metastasis of intra‐abdominal cancers. Intraperitoneal chemotherapy against CRPC is at present the preferred treatment. The aim of this study is to develop a novel hydrogel drug delivery system through the combination of 5‐fluorouracil (5‐FU) loaded polymeric micelles and cisplatin (DDP) in biodegradable thermosensitive chitosan (CS) hydrogel. The prepared CS hydrogel drug is a free‐flowing solution at room temperature and forms a stationary gel at body temperature. Therefore, a CRPC mouse model is established to investigate the antitumor activity of CS hydrogel drug system. The results suggest that intraperitoneal administration of CS hydrogel drug can inhibit tumor growth and metastasis, and prolong survival time compared with other groups, thus improving the chemotherapeutic effect. Ki‐67 immunohistochemical analysis reveals that tumors in the CS hydrogel drug group has lower cell proliferation in contrast to other groups (P < 0.001). Furthermore, hematoxylin‐eosin staining of liver and lung tissue indicates that the CS hydrogel drug has also a certain inhibitory effect on colorectal cancer metastasis to the liver and lung. Hence, the work highlights the potential clinical applications of the CS hydrogel drug.

     

Synthesis of dual responsive cyclotriphosphazene‐based IPN hydrogels for controlled release of chemotherapeutic agent

Dual responsive cyclotriphosphazene (CTP)‐based hydrogels have been synthesized for a controlled release of FU, a hydrophilic drugs. These hydrogels composed of mono (methacryloyl‐2‐ethoxy)‐pentakis(N¹,N¹‐dimethylpropane‐1,3‐diamino)‐cyclotriphosphazene (HEMA (DMPDA)₅CP), acryl amide and pectin were synthesized by free radical polymerization method using methylenebisacrylamide cross linker. The CTP hydrogels were characterized to understand the structure, drug nature in the network and morphology by FTIR, DSC, XRD and SEM, respectively. In this paper, the swelling (dynamic and equilibrium) properties of cyclotriphosphazene hydrogels were investigated, showing dual (pH and thermo) responsiveness and large variation in the swelling capacity. Based on these results the structural parameters of the hydrogel networks such as the average molecular weight between cross‐links (M_c) and polymer–solvent interaction parameter (χ) were determined. The CTP hydrogels has high FU loading efficiency 65 ± 0.5. In‐vitro FU release of these hydrogels was controlled for about 24 hr also hydrogel showed a distinct initial burst. The CTP hydrogels are bearing both hydrophilic groups of pectin and hydrophobic groups of CTP exhibited dual responsive behaviors with pH and temperature. Copyright © 2015 John Wiley & Sons, Ltd.